Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/23318
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorFRANCISCO, Guilherme-
dc.contributor.authorMENEZES, Paulo Rossi-
dc.contributor.authorELUF-NETO, Jose-
dc.contributor.authorCHAMMAS, Roger-
dc.date.accessioned2017-11-27T16:33:55Z-
dc.date.available2017-11-27T16:33:55Z-
dc.date.issued2011-
dc.identifier.citationINTERNATIONAL JOURNAL OF CANCER, v.129, n.4, p.920-930, 2011-
dc.identifier.issn0020-7136-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/23318-
dc.description.abstractArg72Pro is a common polymorphism in TP53, showing differences in its biological functions. Case-control studies have been performed to elucidate the role of Arg72Pro in cancer, although the results are conflicting and heterogeneous. Here, we analyzed pooled data from case-control studies to determine the role of Arg72Pro in different cancer sites. We performed a systematic review and meta-analysis of 302 case-control studies that analyzed Arg72Pro in cancer susceptibility. Odds ratios were estimated for different tumor sites using distinct genetic models, and the heterogeneity between studies was explored using I(2) values and meta-regression. We adopted quality criteria to classify the studies. Subgroup analyses were done for tumor sites according to ethnicity, histological, and anatomical sites. Results indicated that Arg72Pro is associated with higher susceptibility to cancer in some tumor sites, mainly hepatocarcinoma. For some tumor sites, quality of studies was associated with the size of genetic association, mainly in cervical, head and neck, gastric, and lung cancer. However, study quality did not explain the observed heterogeneity substantially. Meta-regression showed that ethnicity, allelic frequency and genotyping method were responsible for a substantial part of the heterogeneity observed. Our results suggest ethnicity and histological and anatomical sites may modulate the penetrance of Arg72Pro in cancer susceptibility. This meta-analysis denotes the importance for more studies with good quality and that the covariates responsible for heterogeneity should be controlled to obtain a more conclusive response about the function of Arg72Pro in cancer.-
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq Brasilia, Brazil-
dc.language.isoeng-
dc.publisherWILEY-BLACKWELL-
dc.relation.ispartofInternational Journal of Cancer-
dc.rightsrestrictedAccess-
dc.subjectArg72Pro-
dc.subjectp53-
dc.subjectmeta-regression-
dc.subjectheterogeneity-
dc.subjectcancer susceptibility-
dc.subjectmeta-analysis-
dc.subjectcase-control-
dc.subject.otherp53 codon-72 polymorphism-
dc.subject.othersquamous-cell carcinoma-
dc.subject.otherbreast-cancer-
dc.subject.otherlung-cancer-
dc.subject.othercervical-cancer-
dc.subject.otherrisk-
dc.subject.othergene-
dc.subject.otherassociation-
dc.subject.othermutations-
dc.subject.otherselection-
dc.titleArg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies-
dc.typearticle-
dc.rights.holderCopyright WILEY-BLACKWELL-
dc.identifier.doi10.1002/ijc.25710-
dc.identifier.pmid20886596-
dc.subject.wosOncology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.description.beginpage920-
hcfmusp.description.endpage930-
hcfmusp.description.issue4-
hcfmusp.description.volume129-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-79959732231-
hcfmusp.origem.idWOS:000292508000017-
hcfmusp.publisher.cityMALDEN-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceHong Y, 2005, CANCER RES, V65, P9582, DOI 10.1158/0008-5472.CAN-05-1460-
hcfmusp.relation.referenceStroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008-
hcfmusp.relation.referenceZhou Y, 2007, INT J CANCER, V121, P1481, DOI 10.1002/ijc.22833-
hcfmusp.relation.referenceHainaut P, 2009, LANCET ONCOL, V10, P913, DOI 10.1016/S1470-2045(09)70198-6-
hcfmusp.relation.referenceHu N, 2003, CANCER DETECT PREV, V27, P132, DOI 10.1016/S0361-090X(03)00031-X-
hcfmusp.relation.referenceDamin APS, 2006, CANCER DETECT PREV, V30, P523, DOI 10.1016/j.cdp.2006.09.007-
hcfmusp.relation.referenceSCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8-
hcfmusp.relation.referenceSjalander A, 1996, HUM HERED, V46, P41, DOI 10.1159/000154324-
hcfmusp.relation.referenceAchatz MIW, 2009, LANCET ONCOL, V10, P920, DOI 10.1016/S1470-2045(09)70089-0-
hcfmusp.relation.referenceHiggins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557-
hcfmusp.relation.referenceWeston A, 1997, CANCER EPIDEM BIOMAR, V6, P105-
hcfmusp.relation.referencePetitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302-
hcfmusp.relation.referenceSjalander A, 1996, CARCINOGENESIS, V17, P1313, DOI 10.1093/carcin/17.6.1313-
hcfmusp.relation.referencePietsch EC, 2006, ONCOGENE, V25, P1602, DOI 10.1038/sj.onc.1209367-
hcfmusp.relation.referenceKalemi TG, 2005, CANCER LETT, V222, P57, DOI 10.1016/j.canlet.2004.11.025-
hcfmusp.relation.referenceYan LL, 2009, INT J CANCER, V125, P2903, DOI 10.1002/ijc.24603-
hcfmusp.relation.referenceTada M, 2001, CARCINOGENESIS, V22, P515, DOI 10.1093/carcin/22.3.515-
hcfmusp.relation.referenceOlivier M, 2009, CANCER GENE THER, V16, P1, DOI 10.1038/cgt.2008.69-
hcfmusp.relation.referenceDumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093-
hcfmusp.relation.referenceBergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879-
hcfmusp.relation.referenceMarin MC, 2000, NAT GENET, V25, P47-
hcfmusp.relation.referenceMakni H, 2000, INT J CANCER, V87, P528, DOI 10.1002/1097-0215(20000815)87:4<528::AID-IJC11>3.3.CO;2-F-
hcfmusp.relation.referencePetitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495-
hcfmusp.relation.referenceDakouras A, 2008, ANTICANCER RES, V28, P1039-
hcfmusp.relation.referenceStorey A, 1998, NATURE, V393, P229-
hcfmusp.relation.referenceWhibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584-
hcfmusp.relation.referenceKlug SJ, 2009, LANCET ONCOL, V10, P772, DOI 10.1016/S1470-2045(09)70187-1-
hcfmusp.relation.referenceHaiman CA, 2006, NEW ENGL J MED, V354, P333, DOI 10.1056/NEJMoa033250-
hcfmusp.relation.referenceBaynes C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1669-
hcfmusp.relation.referenceBECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228-
hcfmusp.relation.referenceBorenstein M, 2009, INTRO METAANALYSIS, P450-
hcfmusp.relation.referenceBROSH R, 2009, NAT REV CANCER, V10, P701-
hcfmusp.relation.referenceBuyru N, 2003, ONCOL REP, V10, P711-
hcfmusp.relation.referenceCosta S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-32-
hcfmusp.relation.referenceEgger M, 2001, SYSTEMATIC REV HLTH, p[xviii, 487]-
hcfmusp.relation.referenceFrancisco G, 2008, EUR J HUM GENET, V16, P724, DOI 10.1038/ejhg.2008.6-
hcfmusp.relation.referenceGaudet MM, 2008, BREAST CANCER RES TR, V108, P93, DOI 10.1007/s10549-007-9573-0-
hcfmusp.relation.referenceGochhait S, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1780-
hcfmusp.relation.referenceHrstka R, 2009, J CELL MOL MED, V13, P440, DOI 10.1111/j.1582-4934.2008.00634.x-
hcfmusp.relation.referenceHuang Xin-En, 2003, Breast Cancer, V10, P307, DOI 10.1007/BF02967650-
hcfmusp.relation.referenceIoannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159-
hcfmusp.relation.referenceKoushik A, 2004, CANCER EPIDEM BIOMAR, V13, P11, DOI 10.1158/1055-9965.EPI-083-3-
hcfmusp.relation.referenceMinelli C, 2009, AM J EPIDEMIOL, V170, P1333, DOI 10.1093/aje/kwp350-
hcfmusp.relation.referenceMurata M, 1996, CARCINOGENESIS, V17, P261, DOI 10.1093/carcin/17.2.261-
hcfmusp.relation.referenceNadji SA, 2007, LUNG CANCER, V56, P145, DOI 10.1016/j.lungcan.2006.12.006-
hcfmusp.relation.referencePopanda O, 2007, LUNG CANCER, V55, P25, DOI 10.1016/j.lungcan.2006.09.006-
hcfmusp.relation.referenceSHAO Y, 2008, DIS ESOPHAGUS, V2, P139-
hcfmusp.relation.referenceSzymanowska A, 2006, LUNG CANCER-J IASLC, V52, P9, DOI 10.1016/j.lungcan.2005.12.007-
hcfmusp.relation.referenceTan XL, 2007, PHARMACOGENET GENOM, V17, P639, DOI 10.1097/FPC.0b013e3280d5121c-
hcfmusp.relation.referenceYang WJ, 2008, MOL CARCINOGEN, V47, P100, DOI 10.1002/mc.20368-
dc.description.indexMEDLINE-
hcfmusp.citation.scopus60-
hcfmusp.scopus.lastupdate2022-08-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDR
Departamento de Radiologia - FM/MDR

Artigos e Materiais de Revistas Científicas - FM/MPR
Departamento de Medicina Preventiva - FM/MPR

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Artigos e Materiais de Revistas Científicas - LIM/38
LIM/38 - Laboratório de Epidemiologia e Imunobiologia


Files in This Item:
File Description SizeFormat 
art_FRANCISCO_Arg72Pro_TP53_polymorphism_and_cancer_susceptibility_a_comprehensive_2011.PDF
  Restricted Access
publishedVersion (English)162.51 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.